Perlecan Maintains Microvessel Integrity In Vivo and Modulates Their Formation In Vitro

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Gustafsson, Erika ^a   Almonte Becerril, Maylin ^b,c   Bloch, Wilhelm ^d   Costell, Mercedes ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF VALENCIA   (Spain)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d Department of Molecular and Cellular Sport Medicine ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; PERLECAN; VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASEMENT MEMBRANE; BLEEDING; BLOOD VESSEL RUPTURE; BRAIN BLOOD VESSEL; CELL FUNCTION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DISEASE SEVERITY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYOID BODY; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN FUNCTION; REGULATORY MECHANISM; SKIN BLOOD VESSEL; SUBENDOTHELIUM; TERATOMA; TUMOR VASCULARIZATION;

ANIMALS; BASEMENT MEMBRANE; BRAIN; EMBRYOID BODIES; EMBRYONIC STEM CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE PROTEOGLYCANS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; SKIN; TERATOMA;

MUS;

EID: 84872180918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053715     Document Type: Article

References (56)

1. Stratman AN, Malotte KM, Mahan RD, Davis MJ, Davis GE, (2009) Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 114: 5091-5101 doi:10.1182/blood-2009-05-222364.
2. Handler M, Yurchenco PD, Iozzo RV (1997) AID-AJA6>3.0.CO;2-H.
3. Murdoch AD, Liu B, Schwarting R, Tuan RS, Iozzo RV, (1994) Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42: 239-249.
4. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y, (1999) Perlecan is essential for cartilage and cephalic development. Nat Genet 23: 354-358 doi:10.1038/15537.
5. Costell M, Gustafsson E, Aszódi A, Mörgelin M, Bloch W, et al. (1999) Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147: 1109-1122.
6. Costell M, Carmona R, Gustafsson E, González-Iriarte M, Fässler R, et al. (2002) Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ Res 91: 158-164.
7. Girós A, Morante J, Gil-Sanz C, Fairén A, Costell M, (2007) Perlecan controls neurogenesis in the developing telencephalon. BMC Dev Biol 7: 29 doi:10.1186/1471-213X-7-29.
8. Sasse P, Malan D, Fleischmann M, Roell W, Gustafsson E, et al. (2008) Perlecan is critical for heart stability. Cardiovasc Res 80: 435-444 doi:10.1093/cvr/cvn225.
9. Peng HB, Xie H, Rossi SG, Rotundo RL, (1999) Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan. J Cell Biol 145: 911-921.
10. Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D, et al. (2000) Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet 26: 480-483 doi:10.1038/82638.
11. Arikawa-Hirasawa E, Le AH, Nishino I, Nonaka I, Ho NC, et al. (2002) Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet 70: 1368-1375 doi:10.1086/340390.
12. Stratman AN, Davis GE, (2012) Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal 18: 68-80 doi:10.1017/S1431927611012402.
13. Wickström SA, Keski-Oja J, Alitalo K, (2003) Matrix reloaded to circulation hits the tumor target. Cancer Cell 3: 513-514.
14. Bix G, Iozzo RV, (2008) Novel interactions of perlecan: unraveling perlecan's role in angiogenesis. Microsc Res Tech 71: 339-348 doi:10.1002/jemt.20562.
15. Segev A, Nili N, Strauss BH, (2004) The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res 63: 603-610 doi:10.1016/j.cardiores.2004.03.028.
16. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, et al. (1998) Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102: 1599-1608 doi:10.1172/JCI3793.
17. Mathiak M, Yenisey C, Grant DS, Sharma B, Iozzo RV, (1997) A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res 57: 2130-2136.
18. Aviezer D, Hecht D, Safran M, Eisinger M, David G, et al. (1994) Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79: 1005-1013.
19. Goyal A, Pal N, Concannon M, Paul M, Doran M, et al. (2011) Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. Journal of Biological Chemistry 286: 25947-25962 doi:10.1074/jbc.M111.243626.
20. Saksela O, Moscatelli D, Sommer A, Rifkin DB, (1988) Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107: 743-751.
21. Kalluri R, (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433 doi:10.1038/nrc1094.
22. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, et al. (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 166: 97-109 doi:10.1083/jcb.200401150.
23. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV, (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278: 4238-4249 doi:10.1074/jbc.M210445200.
24. Feitsma K, Hausser H, Robenek H, Kresse H, Vischer P, (2000) Interaction of thrombospondin-1 and heparan sulfate from endothelial cells. Structural requirements of heparan sulfate. J Biol Chem 275: 9396-9402.
25. Miosge N, Simniok T, Sprysch P, Herken R, (2003) The collagen type XVIII endostatin domain is co-localized with perlecan in basement membranes in vivo. J Histochem Cytochem 51: 285-296.
26. Sakai K, Nakamura T, Matsumoto K, Nakamura T, (2009) Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. J Biol Chem 284: 22491-22499 doi:10.1074/jbc.M109.025148.
27. Chadderton NS, Stringer SE, (2003) Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int J Biochem Cell Biol 35: 1052-1055.
28. Zoeller JJ, Whitelock JM, Iozzo RV, (2009) Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol 28: 284-291 doi:10.1016/j.matbio.2009.04.010.
29. Zhou Z, Wang J, Cao R, Morita H, Soininen R, et al. (2004) Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 64: 4699-4702 doi:10.1158/0008-5472.CAN-04-0810.
30. Rossi M, Morita H, Sormunen R, Airenne S, Kreivi M, et al. (2003) Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J 22: 236-245 doi:10.1093/emboj/cdg019.
31. Montanez E, Piwko-Czuchra A, Bauer M, Li S, Yurchenco P, et al. (2007) Analysis of integrin functions in peri-implantation embryos, hematopoietic system, and skin. Meth Enzymol 426: 239-289 doi:10.1016/S0076-6879(07)26012-4.
32. Bloch W, Forsberg E, Lentini S, Brakebusch C, Martin K, et al. (1997) Beta 1 integrin is essential for teratoma growth and angiogenesis. J Cell Biol 139: 265-278.
33. Yu K, Herr AB, Waksman G, Ornitz DM, (2000) Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 97: 14536-14541 doi:10.1073/pnas.97.26.14536.
34. Flanagan JG, Leder P, (1990) The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 63: 185-194.
35. Carmeliet P, (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395 doi:10.1038/74651.
36. Zoeller JJ, McQuillan A, Whitelock J, Ho S-Y, Iozzo RV, (2008) A central function for perlecan in skeletal muscle and cardiovascular development. J Cell Biol 181: 381-394 doi:10.1083/jcb.200708022.
37. Ishijima M, Suzuki N, Hozumi K, Matsunobu T, Kosaki K, et al. (2012) Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol 31: 234-245 doi:10.1016/j.matbio.2012.02.006.
38. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, et al. (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8: 1875-1887.
39. Lindahl P, Johansson BR, Levéen P, Betsholtz C, (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245.
40. Göhring W, Sasaki T, Heldin CH, Timpl R, (1998) Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur J Biochem 255: 60-66.
41. Kostka G, Giltay R, Bloch W, Addicks K, Timpl R, et al. (2001) Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice. Mol Cell Biol 21: 7025-7034 doi:10.1128/MCB.21.20.7025-7034.2001.
42. Thyboll J, Kortesmaa J, Cao R, Soininen R, Wang L, et al. (2002) Deletion of the laminin alpha4 chain leads to impaired microvessel maturation. Mol Cell Biol 22: 1194-1202.
43. Eklund L, Piuhola J, Komulainen J, Sormunen R, Ongvarrasopone C, et al. (2001) Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice. Proc Natl Acad Sci USA 98: 1194-1199 doi:10.1073/pnas.031444798.
44. Bader BL, Rayburn H, Crowley D, Hynes RO, (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95: 507-519.
45. Zhu J, Motejlek K, Wang D, Zang K, Schmidt A, et al. (2002) beta8 integrins are required for vascular morphogenesis in mouse embryos. Development 129: 2891-2903.
46. Henry MD, Satz JS, Brakebusch C, Costell M, Gustafsson E, et al. (2001) Distinct roles for dystroglycan, beta1 integrin and perlecan in cell surface laminin organization. Journal of Cell Science 114: 1137-1144.
47. Baker AB, Ettenson DS, Jonas M, Nugent MA, Iozzo RV, et al. (2008) Endothelial cells provide feedback control for vascular remodeling through a mechanosensitive autocrine TGF-beta signaling pathway. Circ Res 103: 289-297 doi:10.1161/CIRCRESAHA.108.179465.
48. Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, et al. (2004) Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ Res 94: 175-183 doi:10.1161/01.RES.0000109791.69181.B6.
49. Kinsella MG, Tran P-K, Weiser-Evans MCM, Reidy M, Majack RA, et al. (2003) Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol 23: 608-614 doi:10.1161/01.ATV.0000063109.94810.EE.
50. Tran P-K, Tran-Lundmark K, Soininen R, Tryggvason K, Thyberg J, et al. (2004) Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ Res 94: 550-558 doi:10.1161/01.RES.0000117772.86853.34.
51. Adatia R, Albini A, Carlone S, Giunciuglio D, Benelli R, et al. (1997) Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann Oncol 8: 1257-1261.
52. Risau W, Lemmon V, (1988) Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125: 441-450.
53. Risau W, Sariola H, Zerwes HG, Sasse J, Ekblom P, et al. (1988) Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 102: 471-478.
54. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, et al. (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60: 1388-1393.
55. Kazemi S, Wenzel D, Kolossov E, Lenka N, Raible A, et al. (2002) Differential role of bFGF and VEGF for vasculogenesis. Cell Physiol Biochem 12: 55-62.
56. Dono R, Texido G, Dussel R, Ehmke H, Zeller R, (1998) Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J 17: 4213-4225 doi:10.1093/emboj/17.15.4213.